The Scottish region of Fife has launched one of the world’s first local care frameworks for Huntington’s disease, putting…
Ana de Barros, PhD
Ana holds a PhD in immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. Ana was awarded two FCT fellowships and has won the Portuguese Immunology Society Best Paper and Best Poster award in 2009 and 2010, as well as the CESPU International Research Award in 2010. After leaving the lab to pursue a career in science communication, she served as the director of science communication at iMM Lisbon.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana de Barros, PhD
“You Me Everything,” a novel about a single mom whose mother is diagnosed with Huntington’s disease, is helping…
A Rare Conditions Care Value (RCCV) program providing second opinions from experts for patients with rare diseases like Huntington’s disease was…
AllianceRx Walgreens Prime and Walgreens now have several new limited distribution therapies available for its specialty patients, including…
For Huntington’s Disease Awareness Week, the Huntington’s Disease Association in the U.K. has a few suggestions for ways to bring the community…
Three organizations fighting neurodegenerative diseases have teamed up to challenge researchers around the world to come up with new treatment…
MMJ BioScience received a licence from Health Canada to develop cannabis-derived products based on proprietary formulations for the treatment of…
The Huntington’s Disease Society of America (HDSA) recently announced that 43 Huntington’s disease (HD) care facilities are now…
The U.S. Food and Drug Administration recently granted orphan drug status to Emerald Health’s EHP-102, an investigative therapy for Huntington’s…
Wave Life Sciences and Takeda Pharmaceutical Company are teaming up to develop nucleic acid therapies for central nervous system…